Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing compound doai
Patent
1999-01-04
2000-05-02
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing compound doai
A61K 3104
Patent
active
060573732
ABSTRACT:
The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.
REFERENCES:
patent: 4122193 (1978-10-01), Scherm et al.
patent: 4233229 (1980-11-01), Chakrabarti
patent: 4355043 (1982-10-01), Durlach
patent: 5061703 (1991-10-01), Bormann et al.
patent: 5206248 (1993-04-01), Smith
patent: 5262162 (1993-11-01), Bormann et al.
patent: 5382601 (1995-01-01), Nurnberg et al.
patent: 5455279 (1995-10-01), Lipton
patent: 5602150 (1997-02-01), Lidsky
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5614560 (1997-03-01), Lipton
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5747545 (1998-05-01), Lipton
Alexander, et al., "Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment" Brit. F. Psychiat. 133:143-49, 1978.
Ananth, et al., "Meige's Syndrome Associated with Neuroleptic Treatment", Am J Psychiatry 145:513-515, Apr., 1988.
Andreassen, et al., "Tardive Dyskinesia: Behavioral Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis", Pharmacology Biochemistry and Behavior, 49:309-312, 1994.
Andrew, "Clinical Relationship of Extrapyramidal Symptoms and Tardive Dyskinesia", Can, J. Psych., 39:576-580, 1994.
Arthurs, et al., "Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin" Can J Ophthalmol , 22:24-28, 1987.
Athanassenas, et al., "Serum Calcium and Magnesium Levels in Chronic Schizophrenics", Journal of Clinical Psychopharmacology, 3:212-216, Aug., 1983.
Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neurolepti-Induced Extrapyramidal Symptoms", Can. J. Psych.,m 39:74-84, 1994.
Boumans et al., "Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?", Schizo Bull, 20:339-344, 1994.
Britton, et al., "Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats", Life Sciences, 60:1729-1740, 1997.
Buchel et al., "Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing", Psychopharmacology-Berl, 117:162:165, 1995.
Casey, et al., "Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome", Neurology 30:690-695, Jul., 1980.
Chakos et al., "Incidence and Correlates of Tardive Dyskinesia in First Episide of Schizophrenia", Arch Gen Psychiatry, 53:313-319, 1996.
Chappell, et al., "Future Therapies of Tourette Syndrome", Neurologic Clinics of North America, 15:429-450, May, 1997.
Chen, et al., "Focal Dystonia and Repetitive Motion Disorders", Clinical Orthopaedics and Related Research, 351:102-106, Jun., 1998.
Dabiri, et al., "Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia", Am J Psychiatry 151:925-926, Jun., 1994.
De Leeuw, et al., Effect of Intensive IV + Oral Magnesium Supplementation on Circulating Ion Levels, Lipid Parameters and Metabolic Control in Mg-Depleted Insulin-Dependent Diabetic Patients (IDDM).
De Mattos, et al., "Aspectos Clinicos E Terapeuticos Em 64 Pacientes", Arq Neuropsiquiatr 54(1) 30-36, 1996.
Decker et al., "Amantadine Hydrochloride Treatment of Tardive Dyskinesia", Oct. 7, New England J. Med, 285:860, 1971.
Delfs et al., "Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in an Animal Model of Tardive Dyskinesia", Exp. Neurol. 133:175-188, 1995.
Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro", Arzneimittelforschung, 45:1-5, 1995.
Durlach, et al., "Magnesium Status and Ageing: An Update", Magnesium Research 11:25-42, 1997.
Egan, et al., "Treatment of Tardive Dyskinesia", Schizophrenia Bulletin, 23:583-609, 1997.
Ema, et al., "Alcohol-Induced Vascular Damage of Brain Is Ameliorated by Administration of Magnesium" Alcohol, 15: 95-103, 1998.
Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxoic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 198:215-217, 1991.
Esper, et al., "Adult-Onset Focal Dystonias: Presentation and Treatment Options" Tennessee Medicine, 18-20, Jan., 1997.
Fariello, et al., "Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects From the Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid" Neurology 32:241-245, 1982.
Galardi, et al., "Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis", Acta Neurol Scand 94:172-176, 1996.
Gamez, et al., Serum Concentration and Dietary Intake of Mg and Ca in Institutionalized Elderly People.
Gao et al., "Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats", J. Neural Transmission, 95:63-69, 1994.
Gardos, et al., "The Treatment of Tardive Dyskinesias", Psychopharmacology, 1503-1511, 1995.
Greensmith, et al., "Magnesium Ions Reduce Motoneuron Death Following Nerve Injury or Exposure to N-Methyl-D-Aspartate In The Developing Rat", Neuroscience 68:807-812, 1995.
Gullestad, et al., "Magnesium Status in Health Free-Living Elderly Norwegians", Journal of the American College of Nutrition, 13:45-50, 1994.
Hallett, et al., "The Neurophysiology of Dystonia", Arch Neurol, 55:601-603, May, 1998.
Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia", Clin. Neuropharmacol, 19:390-398, 1996.
Heath, et al., "Neuroprotective Effects of MgSO.sub.4 and MgCl.sub.2 in Closed Head Injury: A Comparative Phosphorus NMR Study", Journal of Neurotrauma, 15:183-189, 1998.
Hoane, et al., "Preoperative Regimens of Magnesium Facilitate Recovery of Function and Prevent Subcortical Atrophy Following Lesions of the Rat Sensorimotor Cortex", Brain Research Bulletin, 45:45-51, 1998.
Holds, et al., "Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm", AFP, 43(6): 2113-2120, Jun., 1991.
Imamura et al., "Improved Preservation with Amantadine", Abstract, No-To-Shinkei, 46:556-562, 1994.
Jacoby, et al., "Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and In Vivo", Investigative Ophthalmology & Visual Science, 31:569-576, Mar. 1990.
Jankovic, J. "Treatment of Hyperkinetic Movement Disorders with Tetrabenazine A Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982.
Jankovic, J. "Blepharospasm and Orofacial-Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients", Ann Neurol 13:402-411, 1983.
Jankovic, J. "Botulinum Toxin in the Treatment of Dystonic Tics", Movement Disorders, 9:347-349, 1994.
Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-765, 1995.
Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur. J. Pharmacol, 219:451-454, 1992.
Kirov, et al., "Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms", Neuropsychobiology 30:73-78, 1994.
Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists", Abstract, Nervenarzt, 67:77-82, 1996.
Krieglstein, et al., "Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage", Neuropharmacology, 35, 1737-1742, 1996.
Kurata, et al., "Meige's Syndrome During Long-Term Neuroleptic Treatment", Jpn J. Psychiatr Neurol 43:627-631, 1989.
Kurlan, R. "Treatment of Tics", Neurologic Clinics of North, May, 1997.
Lam et al., Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dism, 182:113-114, 1994.
Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.
Lichter, et al., "Predictors of Clonidine Response in Tourette Syndrome: Implications and Infere
Kim Vickie Y.
MacMillan Keith D.
Pasternack Sam
Synchroneuron, LLC
LandOfFree
Methods of treating tardive dyskinesia and other movement disord does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating tardive dyskinesia and other movement disord, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating tardive dyskinesia and other movement disord will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1594419